Comparing two groups from lowest to highest scan rate8, patients who scanned more frequently using the FreeStyle Libre systems* spent 43% more Time In Range.
Frequent use of the FreeStyle Libre system also resulted in patients spending 26% less Time Below Range (<3.0 mmol/L)5
Increased testing frequency is sustained over time with the FreeStyle Libre system.9
Learn more about the FreeStyle Libre Portfolio and their benefits for your patients with our FreeStyle Academy
Clinical benefits for a broad range of T1D and
T2D patients.
Explore our training resources to help you to
help your patients understand Time in Range better.
Learn more about Time in Range in our CME
accredited three-module webcast series.
We offer various on-demand webinars for
Healthcare Professionals including
Understanding Time in Range.
Learn more about Time in Range and the
FreeStyle Libre Portfolio through our
Healthcare Professional education modules.
References & Disclaimers
Images are for illustrative purposes only. Not real patient, data or healthcare professional.
* FreeStyle Libre systems refers to the FreeStyle Libre or FreeStyle Libre 2 system
1. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254-2263.
2. Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diab Res Care. 2019. https://doi:10.1136/bmjdrc-2019-000809.
3. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1): 55-73.
4. Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care. 2019;42(7):1178-1184. 2020;43(2):389-397.
5. Lang J, Jangam S, Dunn T, Hayter G. Expanded real-world use reaffirms strong correlation between scanning frequency of flash glucose monitoring and glucose control [Poster 972]. Diabetes. 2019;68(suppl 1). https://doi.org/10.2337/db19-972-P.
6. Deshmukh H, et al. Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit. Diabetes Care 2020;43:2153–2160.
7. From baseline 67.2 mmol/mol HbA1c across the entire study population.
8. Comparing 2 groups from lowest to highest scan rate (3.6 and 39.5 scans/day).
9. Jangam S, Dunn T, Xu Y, Hayter G, Ajjan R. Flash glucose monitoring improves glycemia in higher-risk patients: a longitudinal, observational study under real-life settings. BMJOpen Diab Res Care 2019;7:e000611. DOl:10.1136/bmjdrc-2018-000611.
The "Yes" link below will take you to a website other than Abbott Laboratories. Links to other websites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the content of such websites or any link contained in such websites. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement by Abbott Laboratories of the site.
Do you want to leave this page?
This is a product-specific website intended for HCPs of the European Union and the UK only. If you live in another country, please contact your local Abbott office to obtain the correct product information for your country of residence.